EP2393784A1 - Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable - Google Patents
Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptableInfo
- Publication number
- EP2393784A1 EP2393784A1 EP10707068A EP10707068A EP2393784A1 EP 2393784 A1 EP2393784 A1 EP 2393784A1 EP 10707068 A EP10707068 A EP 10707068A EP 10707068 A EP10707068 A EP 10707068A EP 2393784 A1 EP2393784 A1 EP 2393784A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- compound
- vii
- process according
- synthesis process
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a process for synthesizing ivabradine of formula (I)
- Ivabradine as well as its addition salts with a pharmaceutically acceptable acid, and more particularly its hydrochloride, have very interesting pharmacological and therapeutic properties, especially bradycardic properties, which render these compounds useful in the treatment or prevention of different clinical situations of myocardial ischemia such as angina pectoris, myocardial infarction and associated rhythm disorders, as well as in various pathologies including rhythm disorders, especially supraventricular, and in heart failure.
- A is as defined above, in the presence of a base, in an organic solvent.
- the compound of formula (VII) is in optically active form, and more particularly of configuration (S).
- a pharmaceutically acceptable acid chosen from hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, trifluoroacetic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, tartaric, maleic, citric acids. , ascorbic, oxalic, methanesulfonic, benzenesulphonic and camphoric, and its hydrates.
- a pharmaceutically acceptable acid chosen from hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, trifluoroacetic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, tartaric, maleic, citric acids. , ascorbic, oxalic, methanesulfonic, benzenesulphonic and camphoric, and its hydrates.
- the compound of formula (VII) is in racemic form.
- the alkylation reaction of the racemic compound of formula (VII) with the compound of formula (VIII) is then followed by a step of optical resolution of the compound of formula (VI) obtained. - -
- a pharmaceutically acceptable acid chosen from hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, trifluoroacetic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, tartaric, maleic, citric acids. , ascorbic, oxalic, methanesulfonic, benzenesulphonic and camphoric, and its hydrates.
- a pharmaceutically acceptable acid chosen from hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, trifluoroacetic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, tartaric, maleic, citric acids. , ascorbic, oxalic, methanesulfonic, benzenesulphonic and camphoric, and its hydrates. -o-
- the base preferably used for carrying out the alkylation reaction of the compound of formula (VII) with the compound of formula (VIII) is potassium carbonate.
- the solvent preferentially used to carry out the alkylation reaction of the compound of formula (VII) with the compound of formula (VIII) is acetonitrile.
- the compounds of formula (VIIa) in their racemic or optically active form, in particular cases of the compounds of formula (VII) for which X represents a halogen atom or a mesylate group, are novel products which are useful as synthesis intermediates in the art. chemical or pharmaceutical industry, especially in the synthesis of ivabradine, its addition salts with a pharmaceutically acceptable acid and its hydrates, and are therefore an integral part of the present invention.
- This oil is purified by flash chromatography on 1.5 kg of silica (eluent: dichloromethane / ethanol / NH 4 OH: 80/20/2). 42 g of expected product are obtained in the form of a white solid.
- Step 1 tert-Butyl [3- (7,8-dimethoxy-2-oxo-1,2-dihydro-5-yl) benzazepin-3-yl) propyl] methyl carbamate
- Step 2 7,8-Dimethoxy-3 - [3 - (methylamino) propyl] -1,3-dihydro-2H-3-benzazepin-2-one
- IR (neat): ⁇ 3400, 1651, 1610, 1510, 856, 710 cm -1 .
- dichloromethane an exotherm of 20 ° C up to 28 ° C is observed.
- the mixture is stirred for 12 hours at room temperature.
- An insoluble material is filtered and then evaporated to dryness to obtain 15 g of a residue in the form of an oil.
- Example 5 2.1 g of the racemic compound obtained in Example 5 are separated on a 60 cm x 60 mm column packed with 2.1 kg of Chiralpak® AD phase (particle size 20 ⁇ m).
- the eluent used is an ethanol / acetonitrile / diethylamine mixture (10/90 / 0.1 by volume) at a flow rate of 50 mL / min.
- the associated ultraviolet detector is used at a wavelength of 280 nm.
- 0.95 g of enantiomer of configuration (R) is obtained in the form of white meringue and 0.95 g of enantiomer of configuration (S) also in the form of white meringue.
- IR (neat): ⁇ 1656, 1607, 1511, 1273, 1206, 1101, 836, 760 cm -1 .
- Example 7 1.4 g of the racemic compound obtained in Example 7 are separated on a 60 cm x 60 mm column packed with 3 kg of Chiralpak® T101 phase (particle size 20 ⁇ m).
- the eluent used is an ethanol / acetonitrile / diethylamine mixture (10/90 / 0.1 by volume) at a flow rate of 100 ml / min.
- the associated ultraviolet detector is used at a wavelength of 280 nm.
- 0.56 g of the enantiomer of configuration (R) is obtained in the form of a colorless oil and then 0.62 g of the enantiomer of configuration (S) also in the form of a colorless oil.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0900457A FR2941695B1 (fr) | 2009-02-04 | 2009-02-04 | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
PCT/FR2010/000080 WO2010089475A1 (fr) | 2009-02-04 | 2010-02-03 | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2393784A1 true EP2393784A1 (fr) | 2011-12-14 |
Family
ID=40800462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10707068A Withdrawn EP2393784A1 (fr) | 2009-02-04 | 2010-02-03 | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
Country Status (20)
Country | Link |
---|---|
US (1) | US8415468B2 (ja) |
EP (1) | EP2393784A1 (ja) |
JP (1) | JP5563600B2 (ja) |
KR (1) | KR20110112467A (ja) |
CN (1) | CN102300849A (ja) |
AR (1) | AR075227A1 (ja) |
AU (1) | AU2010210054B2 (ja) |
BR (1) | BRPI1008841A2 (ja) |
CA (1) | CA2750089C (ja) |
EA (1) | EA019465B1 (ja) |
FR (1) | FR2941695B1 (ja) |
GE (1) | GEP20135960B (ja) |
MA (1) | MA33027B1 (ja) |
MX (1) | MX2011007978A (ja) |
MY (1) | MY156630A (ja) |
NZ (1) | NZ594087A (ja) |
SG (1) | SG172913A1 (ja) |
UA (1) | UA101091C2 (ja) |
WO (1) | WO2010089475A1 (ja) |
ZA (1) | ZA201105172B (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8212026B2 (en) | 2007-05-30 | 2012-07-03 | Ind-Swift Laboratories Limited | Process for the preparation of ivabradine hydrochloride and polymorph thereof |
FR2971507B1 (fr) * | 2011-02-14 | 2013-01-18 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR2984320B1 (fr) * | 2011-12-20 | 2013-11-29 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR2984319B1 (fr) * | 2011-12-20 | 2013-12-27 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR2988720B1 (fr) * | 2012-03-27 | 2014-03-14 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
CN103848789B (zh) * | 2012-11-29 | 2016-05-18 | 江苏恒瑞医药股份有限公司 | 一种伊伐布雷定的制备方法 |
FR3003859B1 (fr) * | 2013-03-26 | 2015-03-13 | Servier Lab | "procede de synthese de derives de la 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one et application a la synthese de l'ivabradine" |
EP3101010A1 (en) | 2015-06-03 | 2016-12-07 | Urquima S.A. | New method for the preparation of highly pure ivabradine base and salts thereof |
US10177698B1 (en) | 2017-11-06 | 2019-01-08 | The Boeing Company | Counter-field winding in electrical generator |
CN113372273B (zh) * | 2020-03-10 | 2023-05-09 | 鲁南制药集团股份有限公司 | 一种伊伐布雷定中间体化合物iv |
CN113372274B (zh) * | 2020-03-10 | 2023-03-24 | 鲁南制药集团股份有限公司 | 一种伊伐布雷定的制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3119874A1 (de) * | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel" |
DE3640641A1 (de) * | 1986-11-28 | 1988-07-14 | Thomae Gmbh Dr K | Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
FR2671350A1 (fr) * | 1991-01-08 | 1992-07-10 | Adir | Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant. |
FR2681862B1 (fr) * | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
FR2868777B1 (fr) * | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
EP2097383B1 (en) * | 2006-11-30 | 2012-02-08 | Cadila Healthcare Limited | Process for preparation of ivabradine hydrochloride |
WO2008125006A1 (fr) * | 2007-04-12 | 2008-10-23 | Utopharm (Shanghai) Co., Ltd | Procédés de préparation du chlorhydrate d'ivabradine et de sa forme cristalline stable |
-
2009
- 2009-02-04 FR FR0900457A patent/FR2941695B1/fr not_active Expired - Fee Related
-
2010
- 2010-02-03 MA MA34066A patent/MA33027B1/fr unknown
- 2010-02-03 CA CA2750089A patent/CA2750089C/fr not_active Expired - Fee Related
- 2010-02-03 SG SG2011049913A patent/SG172913A1/en unknown
- 2010-02-03 AR ARP100100290A patent/AR075227A1/es not_active Application Discontinuation
- 2010-02-03 CN CN2010800061486A patent/CN102300849A/zh active Pending
- 2010-02-03 JP JP2011548741A patent/JP5563600B2/ja active Active
- 2010-02-03 GE GEAP201012356A patent/GEP20135960B/en unknown
- 2010-02-03 KR KR1020117020545A patent/KR20110112467A/ko not_active Application Discontinuation
- 2010-02-03 WO PCT/FR2010/000080 patent/WO2010089475A1/fr active Application Filing
- 2010-02-03 UA UAA201110459A patent/UA101091C2/ru unknown
- 2010-02-03 NZ NZ594087A patent/NZ594087A/xx not_active IP Right Cessation
- 2010-02-03 BR BRPI1008841-5A patent/BRPI1008841A2/pt not_active Application Discontinuation
- 2010-02-03 MX MX2011007978A patent/MX2011007978A/es active IP Right Grant
- 2010-02-03 EP EP10707068A patent/EP2393784A1/fr not_active Withdrawn
- 2010-02-03 EA EA201101147A patent/EA019465B1/ru not_active IP Right Cessation
- 2010-02-03 US US13/138,333 patent/US8415468B2/en not_active Expired - Fee Related
- 2010-02-03 AU AU2010210054A patent/AU2010210054B2/en not_active Ceased
- 2010-02-03 MY MYPI2011700105A patent/MY156630A/en unknown
-
2011
- 2011-07-13 ZA ZA2011/05172A patent/ZA201105172B/en unknown
Non-Patent Citations (1)
Title |
---|
REIFFEN M ET AL: "Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a new class of compounds exerting antiischaemic properties", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 33, no. 5, 1 May 1990 (1990-05-01), pages 1496 - 1504, XP002205593, ISSN: 0022-2623, DOI: 10.1021/JM00167A033 * |
Also Published As
Publication number | Publication date |
---|---|
AU2010210054A1 (en) | 2011-08-04 |
GEP20135960B (en) | 2013-11-11 |
CN102300849A (zh) | 2011-12-28 |
SG172913A1 (en) | 2011-08-29 |
EA201101147A1 (ru) | 2012-03-30 |
AR075227A1 (es) | 2011-03-16 |
ZA201105172B (en) | 2012-09-26 |
MA33027B1 (fr) | 2012-02-01 |
WO2010089475A1 (fr) | 2010-08-12 |
JP5563600B2 (ja) | 2014-07-30 |
FR2941695B1 (fr) | 2011-02-18 |
US20110294999A1 (en) | 2011-12-01 |
KR20110112467A (ko) | 2011-10-12 |
MY156630A (en) | 2016-03-15 |
MX2011007978A (es) | 2011-08-15 |
BRPI1008841A2 (pt) | 2020-05-26 |
FR2941695A1 (fr) | 2010-08-06 |
CA2750089A1 (fr) | 2010-08-12 |
EA019465B1 (ru) | 2014-03-31 |
UA101091C2 (ru) | 2013-02-25 |
US8415468B2 (en) | 2013-04-09 |
JP2012516880A (ja) | 2012-07-26 |
NZ594087A (en) | 2013-03-28 |
CA2750089C (fr) | 2013-10-08 |
AU2010210054B2 (en) | 2012-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2202225B1 (fr) | Nouveau procédé de synthèse de l'ivabradine et de ses sels d'addition à un acide pharmaceutiquemenet acceptable | |
CA2750089C (fr) | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable | |
EP1614687B1 (fr) | Nouveau procédé de synthèse de dérivés de la 1,3,4,5-tétrahydro-2H-3-benzazépin-2-one, et application à la synthèse de l'ivabradine et de ses sels d'addition à un acide pharmaceutiquement acceptable | |
EP2241553B1 (fr) | Procédé de synthèse de l'ivabradine et de ses sels d'addition à un acide pharmaceutiquement acceptable | |
CA2773064C (fr) | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable | |
EP2487158B1 (fr) | Nouveau procédé de synthèse de l'ivabradine et de ses sels d'addition à un acide pharmaceutiquement acceptable | |
EP2241554B1 (fr) | Nouveau procédé de synthèse de l'ivabradine et de ses sels d'addition à un acide pharmaceutiquement acceptable | |
EP2364972B1 (fr) | "Nouveau procédé de synthese de l'Ivabradine et de ses sels d'Addition" | |
EP2719689A1 (fr) | Nouveau procede de synthese du 3-(2-bromo-4,5-dimethoxphenyl)propanenitrile, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110711 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
17Q | First examination report despatched |
Effective date: 20121211 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20160301 |